# EORTC

Source: https://onco.cc/companies/curie-nki-eortc/  
OnCo record `curie-nki-eortc` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EORTC is Europe's academic cancer trials organisation and has run practice-changing trials since 1962.

## Summary

EORTC, the European Organisation for Research and Treatment of Cancer in Brussels, is Europe's academic cancer trials organisation and has run practice-changing trials since 1962. Its record includes the sarcoma hyperthermia trial 62961, the melanoma adjuvant trial 1325, the glioma trial 26951 and Stupp's 2005 trial that added temozolomide to radiotherapy for glioblastoma, together with the QLQ-C30 quality of life instruments, with Alexander Eggermont, Denis Lacombe, Michael Weller and Roger Stupp among the people OnCo lists. It is linked to bottlenecks on rare cancers without markets and undervalued quality of life, and to ideas such as mutual recognition of ethics review across countries. How an academic group sustains phase 3 trials that no company will pay for is the standing question. Its trial and quality of life programmes are listed in the notes.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Also known as: European Organisation for Research and Treatment of Cancer; European Organisation for Research and Treatment of Cancer - EORTC
- Tags: cooperative-group
- HQ: Brussels
- Type: cooperative-group
- Website: https://www.eortc.org

## Notes

- Academic phase 3 trials
- Quality of life research

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/European_Organisation_for_Research_and_Treatment_of_Cancer
- Official website: https://www.eortc.org

## Connected records

- trials: [AMAROS (EORTC 10981-22023)](https://onco.cc/trials/amaros/), [CATNON (EORTC 26053-22054)](https://onco.cc/trials/catnon/), [CCTG CE.6 / EORTC 26062-22061 (Perry trial)](https://onco.cc/trials/cctg-ce6/), [CLOCC](https://onco.cc/trials/clocc/), [Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia](https://onco.cc/trials/nct00002719/), [CONVERT](https://onco.cc/trials/convert/), [EORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancer](https://onco.cc/trials/slotman-pci-es-sclc/), [EORTC 10801](https://onco.cc/trials/eortc-10801/), [EORTC 1607: pembrolizumab with cisplatin and gemcitabine in biliary tract cancer](https://onco.cc/trials/eortc-1607-pembro-cisgem/), [EORTC 22033-26033](https://onco.cc/trials/eortc-22033/), [EORTC 22863](https://onco.cc/trials/eortc-22863/), [EORTC 22881-10882 (boost against no boost)](https://onco.cc/trials/eortc-22881-boost/), [EORTC 22911](https://onco.cc/trials/eortc-22911/), [EORTC 22922/10925](https://onco.cc/trials/eortc-22922/), [EORTC 22961](https://onco.cc/trials/eortc-22961/), [EORTC 22991](https://onco.cc/trials/eortc-22991/), [EORTC 26951](https://onco.cc/trials/eortc-26951/), [EORTC 26981 / NCIC CE.3 (Stupp trial)](https://onco.cc/trials/eortc-26981/), [EORTC 40983](https://onco.cc/trials/eortc-40983/), [EORTC 62012](https://onco.cc/trials/eortc-62012/), [MINDACT](https://onco.cc/trials/mindact/), [PEACE-3 (EORTC 1333)](https://onco.cc/trials/peace-3/), [STRASS (EORTC 62092)](https://onco.cc/trials/strass/)
- people: [Alexander Eggermont](https://onco.cc/people/alexander-eggermont/), [Denis Lacombe](https://onco.cc/people/denis-lacombe/), [Michael Weller](https://onco.cc/people/michael-weller/), [Roger Stupp](https://onco.cc/people/roger-stupp/), [Ulrich Keilholz](https://onco.cc/people/ulrich-keilholz/)
- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Inflammatory myofibroblastic tumour (IMT)](https://onco.cc/cancers/inflammatory-myofibroblastic-tumour/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- bottlenecks: [Rare and paediatric cancers without markets](https://onco.cc/bottlenecks/b-rare-cancers/), [Secrecy and intellectual property block collaboration](https://onco.cc/bottlenecks/b-ip-collaboration/), [Surgery and radiotherapy cure most, get least](https://onco.cc/bottlenecks/b-surgery-radiation-innovation/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)
- ideas: [A fixed share of trial-group funding for getting proven care to patients](https://onco.cc/ideas/idea-fund-implementation-quota/), [A global first-in-human network for academic cancer trials with single ethics review](https://onco.cc/ideas/idea-fund-global-academic-phase-one-network/), [A national non-profit contract research organisation for academic oncology trials](https://onco.cc/ideas/idea-fund-public-nonprofit-cro/), [Drop the 'must speak English' rule: translated consent and questionnaires as standard](https://onco.cc/ideas/idea-tr1-language-access-in-trials/), [Mutual recognition of ethics review across countries](https://onco.cc/ideas/idea-tr1-mutual-recognition-ethics-review/), [One global rare cancer network with n-of-1 and Bayesian trial frameworks](https://onco.cc/ideas/idea-moon-rare-cancer-global-network/), [Open-source protocol and statistical analysis plan templates with runnable code](https://onco.cc/ideas/idea-tr1-open-protocol-and-sap-library/), [Time to treatment failure and quality of life as co-primary endpoints in non-curative trials](https://onco.cc/ideas/idea-tr1-ttf-and-qol-coprimary/), [Trial-in-a-box: a preconfigured protocol kit any hospital can open for a rare cancer](https://onco.cc/ideas/idea-tr1-rare-cancer-trial-in-a-box/)
- key papers: [Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma](https://onco.cc/key-papers/paper-stupp-temozolomide-nejm-2005/)
- institutions: [Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH](https://onco.cc/institutions/ccc-vienna/), [European Cancer Organisation](https://onco.cc/institutions/ecco/), [European Medicines Agency](https://onco.cc/institutions/ema/), [European Society for Radiotherapy and Oncology](https://onco.cc/institutions/estro/), [European Society of Surgical Oncology](https://onco.cc/institutions/esso/), [Institut Jules Bordet](https://onco.cc/institutions/institut-jules-bordet/), [International Society for Quality of Life Research](https://onco.cc/institutions/isoqol/), [Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne](https://onco.cc/institutions/chuv-lausanne/), [Maria Skłodowska-Curie National Research Institute of Oncology](https://onco.cc/institutions/nio-warsaw/), [Princess Máxima Center for Pediatric Oncology](https://onco.cc/institutions/princess-maxima/), [SIOP Europe (European Society for Paediatric Oncology)](https://onco.cc/institutions/siop-europe/), [University Hospital Zurich / Comprehensive Cancer Center Zurich](https://onco.cc/institutions/usz-zurich/), [UZ Leuven / Leuven Cancer Institute](https://onco.cc/institutions/uz-leuven/)
- companies: [ARCAGY-GINECO](https://onco.cc/companies/arcagy-gineco/), [Intergroupe Francophone de Cancérologie Thoracique](https://onco.cc/companies/ifct/)

---
JSON: https://onco.cc/api/v1/entities/curie-nki-eortc.json